51.88
price up icon0.91%   0.47
after-market Handel nachbörslich: 51.88
loading
Schlusskurs vom Vortag:
$51.41
Offen:
$51.16
24-Stunden-Volumen:
858.67K
Relative Volume:
0.58
Marktkapitalisierung:
$4.35B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-269.44M
KGV:
-13.83
EPS:
-3.75
Netto-Cashflow:
$-262.63M
1W Leistung:
-5.74%
1M Leistung:
+2.27%
6M Leistung:
+84.76%
1J Leistung:
+131.81%
1-Tages-Spanne:
Value
$51.08
$52.60
1-Wochen-Bereich:
Value
$51.08
$57.35
52-Wochen-Spanne:
Value
$21.02
$58.40

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name
Firmenname
Akero Therapeutics Inc
Name
Telefon
650-487-6488
Name
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
69
Name
Twitter
@akerotx
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
AKRO's Discussions on Twitter

Vergleichen Sie AKRO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AKRO
Akero Therapeutics Inc
51.88 4.35B 0 -269.44M -262.63M -3.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-30 Hochstufung BofA Securities Neutral → Buy
2025-01-27 Bestätigt H.C. Wainwright Buy
2024-11-18 Eingeleitet Citigroup Buy
2024-04-22 Fortgesetzt BofA Securities Neutral
2023-09-19 Eingeleitet Cantor Fitzgerald Overweight
2023-08-28 Eingeleitet UBS Buy
2023-01-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-09-14 Hochstufung Evercore ISI In-line → Outperform
2021-10-19 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-09-10 Eingeleitet BofA Securities Buy
2021-02-26 Eingeleitet Guggenheim Buy
2020-09-10 Eingeleitet Morgan Stanley Overweight
2020-07-20 Bestätigt H.C. Wainwright Buy
2020-07-07 Eingeleitet Chardan Capital Markets Buy
2020-07-01 Bestätigt H.C. Wainwright Buy
2020-03-02 Eingeleitet H.C. Wainwright Buy
2020-02-10 Eingeleitet Canaccord Genuity Buy
2019-07-15 Eingeleitet Evercore ISI Outperform
2019-07-15 Eingeleitet JP Morgan Overweight
2019-07-15 Eingeleitet Jefferies Buy
2019-07-15 Eingeleitet ROTH Capital Buy
Alle ansehen

Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten

pulisher
Jun 18, 2025

Akero Therapeutics (NASDAQ:AKRO) Stock Price Down 3.3%Time to Sell? - MarketBeat

Jun 18, 2025
pulisher
Jun 15, 2025

Don't Ignore The Insider Selling In Akero Therapeutics - simplywall.st

Jun 15, 2025
pulisher
Jun 15, 2025

Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 2,803 Shares of Stock - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 919 Shares of Stock - MarketBeat

Jun 15, 2025
pulisher
Jun 14, 2025

Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 2,493 Shares of Stock - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $127,332.00 in Stock - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $151,387.96 in Stock - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Rhumbline Advisers Purchases 5,001 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Millennium Management LLC Lowers Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Akero Therapeutics (AKRO) Emerges as Attractive Acquisition Targ - GuruFocus

Jun 14, 2025
pulisher
Jun 14, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by SG Americas Securities LLC - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased By Stocktwits - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased - MSN

Jun 13, 2025
pulisher
Jun 13, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $668,625.00 in Stock - MarketBeat

Jun 13, 2025
pulisher
Jun 13, 2025

Investors Buy Large Volume of Call Options on Akero Therapeutics (NASDAQ:AKRO) - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $1,376,000.00 in Stock - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells 37,837 Shares of Stock - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Akero Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

(AKRO) Technical Data - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat

Jun 12, 2025
pulisher
Jun 10, 2025

Transcript : Akero Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 02 - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Day 8 of Gains Streak for Akero Therapeutics Stock with 21% Return (vs. 97% YTD) [6/9/2025] - Trefis

Jun 10, 2025
pulisher
Jun 09, 2025

MASH Market Size in the 7MM was ~USD 1.8 billion in 2023, is projected to grow at a CAGR of 24%, estimates DelveInsight - The Globe and Mail

Jun 09, 2025
pulisher
Jun 09, 2025

Akero Therapeutics' Chief Scientific Officer Sells Shares - TradingView

Jun 09, 2025
pulisher
Jun 09, 2025

Rumor Fuels Akero Therapeutics (AKRO) Stock Movement | AKRO Stoc - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Rumor Fuels Akero Therapeutics (AKRO) Stock Movement | AKRO Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 08, 2025

Ameriprise Financial Inc. Purchases Shares of 15,172 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Jun 08, 2025
pulisher
Jun 08, 2025

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 4,000 Shares - MarketBeat

Jun 08, 2025
pulisher
Jun 08, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 08, 2025
pulisher
Jun 08, 2025

2025-06-08 | Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation | NDAQ:AKRO | Press Release - Stockhouse

Jun 08, 2025
pulisher
Jun 08, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Bank of America Corp DE Sells 93,294 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Jun 07, 2025
pulisher
Jun 07, 2025

Day 7 of Gains Streak for Akero Therapeutics Stock with 20% Return (vs. 95% YTD) [6/6/2025] - Trefis

Jun 07, 2025
pulisher
Jun 06, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) versus Akero Therapeutics (NASDAQ:AKRO) Financial Contrast - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

Ameriprise Financial Inc. Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Akero Therapeutics Elects New Directors at Annual Meeting - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Two Sigma Advisers LP Acquires 27,200 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Bank of America Corp DE Has $1.84 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out - ACCESS Newswire

Jun 03, 2025

Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Akero Therapeutics Inc-Aktie (AKRO) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Cheng Andrew
President and CEO
Jun 18 '25
Sale
54.84
6,620
363,041
549,867
Gangloff Scott A.
Chief Technology Officer
Jun 18 '25
Sale
54.84
848
46,504
23,452
Lamy Patrick
Senior VP, Commercial Strategy
Jun 20 '25
Sale
54.59
875
47,766
31,698
Rolph Timothy
Chief Scientific Officer
Jun 18 '25
Sale
54.84
1,129
61,914
166,234
White William Richard
Chief Financial Officer
Jun 18 '25
Sale
54.84
1,634
89,609
57,521
Yale Catriona
Chief Development Officer
Jun 18 '25
Sale
54.84
1,633
89,554
90,598
Young Jonathan
Chief Operating Officer
Jun 18 '25
Sale
54.84
1,453
79,683
196,594
Yale Catriona
Chief Development Officer
Jun 16 '25
Option Exercise
21.10
10,000
211,000
102,231
Yale Catriona
Chief Development Officer
Jun 16 '25
Sale
54.23
10,000
542,306
92,231
Lamy Patrick
Senior VP, Commercial Strategy
Jun 16 '25
Option Exercise
19.87
2,000
39,740
34,573
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):